This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
Power calculations were performed a posteriori. These suggested that the study had a power of 80% to detect a difference of 20% in readmission rates at 5% significance level. A total of 1,006 patients were admitted to the emergency department of the study hospital from November 1996 to May 1998. Of these, 798 were not eligible due to the obligatory nature of admission (353), weekend referrals (288), co-existing medical conditions (140), or poor social circumstances (17). Twenty-four of the 208 remaining patients refused to participate (reasons not reported). Thus, the final sample enrolled in the analysis included 184 patients. There were 122 patients in the home support group and 62 in the hospital group. The mean age in the home support group was 68.5 years (range: 39 -84) and 48.4% of the patients were women. The mean age in the hospital group was 69.9 years (range: 51 -86) and 61.3% of the patients were women.
Study design
This was an open randomised controlled trial, which was carried out in a single centre. Randomisation was performed using a set of computer-generated sequences of random numbers in a 2:1 ratio (home support group versus hospital group). The patients were followed for 8 weeks. A final assessment was conducted on 79 patients in the home support group and 28 patients in the hospital group.
Analysis of effectiveness
The basis of the analysis of the clinical study (intention to treat or treatment completers only) was not stated. The primary health outcomes used in the effectiveness study were: the number of respiratory and non-respiratory readmissions before and after discharge; the median days under hospital or ARAS care, and the mean follow-up visits by ARAS nurses and GP visits between referral and discharge; GP visits and increased carer visits between discharge and final assessment; changes in respiratory parameters, such as respiratory rate, peak expiratory flow, forced expiratory volume in one second (FEV1), and oxygen saturation, both between initial and discharge assessments and between discharge and final assessments; patient satisfaction, as measured using the Chronic Respiratory Questionnaire; and GP satisfaction, measured through a short postal questionnaire.
The study groups were shown to have been comparable at baseline in terms of their age, gender, smoking status, home circumstances and clinical conditions. The authors reported that patients excluded because of weekend admission were more likely to have been housebound or with peripheral oedema than those included in the final sample.
Effectiveness results
Before discharge, the number of respiratory readmissions was 9 in the home support group and 0 in the hospital group. The number of non-respiratory readmissions was 3 (home support) and 0 (hospital), respectively, and one patient in the hospital group died.
After discharge the number of respiratory readmissions was 23 in the home support group and 19 in the hospital group. The number of non-respiratory readmissions was 4 (home support) and 2 (hospital), respectively, and 4 (home support) and 6 (hospital) patients died.
Between referral and discharge, the median days of care were 7 in the home support group and 5 in the hospital group, (p<0.01); in the home support group, the mean follow-up visits by ARAS nurses were 3.8 and there were 0.85 GP visits per 100
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Between discharge and final assessment, the GP visits per 100 patient-days were 0.70 in the home support group and 1.07 in the hospital group, and the rate of increased career visits was 21% (home support) and 36% (hospital), respectively.
Between initial and discharge assessment, the changes in respiratory parameters in the home support group were -2.1 beats/minute for respiratory rate, 40.3 L for peak expiratory flow, 0.16 L for FEV1 and 2.8% for oxygen saturation. The corresponding changes in the hospital group were -2.4 beats/minute (respiratory rate), 21.9 L (peak expiratory flow), 0.06 L (FEV1) and 1.4% (oxygen saturation).
Between discharge and final assessment, the changes in respiratory parameters in the home support group were 0.2 beats/minute for respiratory rate, -12.6 L/minute for peak expiratory flow, -0.06 L for FEV1 and -0.75% for oxygen saturation. The corresponding changes in the hospital group were -0.6 beats/minute (respiratory rate), 10.3 L/minute (peak expiratory flow), 0.14 L (FEV1) and 2.4% (oxygen saturation).
The changes in respiratory parameters changed significantly from baseline to assessment and were comparable across the study groups.
Sixty-nine per cent of the patients in the home support group replied to the questionnaires on satisfaction. Of these, 95% said they were completely satisfied with the service.
About 50% of the GPs replied to the questionnaire and all were satisfied with the new service, which did not increase the demand for their services.
Clinical conclusions
The effectiveness analysis showed that the ARAS was as safe and effective as standard care in improving respiratory functions in patients with exacerbations of COPD. There was a trend towards fewer hospital readmissions after discharge in the intervention group (25%) than in the comparison group (34%), but this difference did not reach statistical significance.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore conducted.
Direct costs
Discounting was not applied since the costs per patients were incurred over a short time period. The unit costs were not reported separately from quantities of resources used. The health services included in the economic evaluation were ARAS (staffing, non-staffing, and drug costs depending on the length of service), inpatient costs, and GP service.
Figures for these resources were not reported in the paper, only the total mean health service cost was reported. The cost/resource boundary adopted in the study appears to have been that of the NHS. The costs were estimated from the average costs per bed-day in the respiratory units and Personal and Social Services Research Unit. A specific evaluation of the costs was carried out for ARAS items. Resource consumption was estimated alongside the effectiveness trial, between November 1996 and May 1998, and 1997 to 98 prices were used for the costs.
Statistical analysis of costs
The costs were treated deterministically.
